About OncoResponse
OncoResponse is a company based in Seattle (United States) founded in 2015 by Clifford J Stocks.. OncoResponse has raised $149.62 million across 10 funding rounds from investors including ARE, Rice University and Takeda Pharmaceuticals. The company has 35 employees as of December 31, 2022. OncoResponse offers products and services including Technology Platform and Monoclonal Antibodies. OncoResponse operates in a competitive market with competitors including Moderna, BeiGene, Incyte, Regeneron Pharmaceuticals and MorphoSys, among others.
- Headquarter Seattle, United States
- Employees 35 as on 31 Dec, 2022
- Founders Clifford J Stocks
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Oncoresponse, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$149.62 M (USD)
in 10 rounds
-
Latest Funding Round
$6 M (USD), Series D
Apr 21, 2025
-
Investors
ARE
& 18 more
-
Employee Count
35
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of OncoResponse
OncoResponse offers a comprehensive portfolio of products and services, including Technology Platform and Monoclonal Antibodies. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for discovering antibodies from elite responders.
Antibodies targeting immunosuppressive elements in tumors.
Unlock access to complete
Unlock access to complete
Leadership Team
10 people
Advisor Team
7 people
Finance and Accounting
1 people
Unlock access to complete
Funding Insights of OncoResponse
OncoResponse has successfully raised a total of $149.62M across 10 strategic funding rounds. The most recent funding activity was a Series D round of $6 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 10
- Last Round Series D — $6.0M
-
First Round
First Round
(06 Oct 2015)
- Investors Count 19
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2025 | Amount | Series D - OncoResponse | Valuation |
investors |
|
| May, 2023 | Amount | Grant - OncoResponse | Valuation |
investors |
|
| May, 2023 | Amount | Series D - OncoResponse | Valuation | RiverVest Venture Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in OncoResponse
OncoResponse has secured backing from 19 investors, including institutional and venture fund investors. Prominent investors backing the company include ARE, Rice University and Takeda Pharmaceuticals. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Early-stage healthcare investments are made by 3B Future Health Fund.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on life science companies
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by OncoResponse
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - OncoResponse
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Oncoresponse Comparisons
Competitors of OncoResponse
OncoResponse operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, Regeneron Pharmaceuticals and MorphoSys, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Antibodies are developed for treating cancer, eye, and inflammatory diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutic antibodies for cancer and other diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Oncoresponse
Frequently Asked Questions about OncoResponse
When was OncoResponse founded?
OncoResponse was founded in 2015.
Where is OncoResponse located?
OncoResponse is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Who is the current CEO of OncoResponse?
Clifford J Stocks is the current CEO of OncoResponse. They have also founded this company.
Is OncoResponse a funded company?
OncoResponse is a funded company, having raised a total of $149.62M across 10 funding rounds to date. The company's 1st funding round was a Series D of $14M, raised on Oct 06, 2015.
How many employees does OncoResponse have?
As of Dec 31, 2022, the latest employee count at OncoResponse is 35.
What does OncoResponse do?
OncoResponse was founded in 2015 and is headquartered in Seattle, United States. Focus is placed on the biotechnology sector, where immunotherapies for cancer are advanced through a proprietary technology platform. Human antibodies are discovered, and an immune checkpoint inhibitor is developed. The lead candidate, OR2805, targets multiple tumor types. Operations emphasize research and development in oncology.
Who are the top competitors of OncoResponse?
OncoResponse's top competitors include Moderna, BeiGene and Regeneron Pharmaceuticals.
What products or services does OncoResponse offer?
OncoResponse offers Technology Platform and Monoclonal Antibodies.
Who are OncoResponse's investors?
OncoResponse has 19 investors. Key investors include ARE, Rice University, Takeda Pharmaceuticals, Oxford Finance, and Arch Venture Partners.